Cyxone initiates early operations with a global contract research organization to conduct Phase 2b trial in rheumatoid arthritis

Cyxone (publ) announces today that the company has initiated an early operations agreement (EOA) with an internationally renowned contract research organization (CRO) to prepare for the upcoming clinical Phase 2b trial of Rabeximod in patients with rheumatoid arthritis. As part of the EOA, the CRO will support Cyxone in start-up and feasibility activities including finalization of the trial protocol and selection of the countries and trial sites that meet the criteria of the trial design.

Cyxone is developing Rabeximod, an oral potential first line treatment for patients suffering from the inflammatory disease rheumatoid arthritis (RA). Currently many patients are underserved as they do not respond to current therapies or stop responding over time. Rabeximod is differentiated from current therapies by suppressing a population of inflammatory cells central to the structural damage of the joints which occurs in RA. By suppressing these cells and by inhibiting the production of proinflammatory signaling molecules critical to drive the inflammatory process, Rabeximod has the potential to treat patients which do not respond to or cannot tolerate other treatments and to prevent the disease progression in a novel and disease modifying manner.

The trial will be randomized and double-blinded, composed by three arms comparing two different dose levels of Rabeximod on top of standard of care to standard of care over a 16-week-treatment period. Patient enrollment is expected to run over 12-18 months.

"As we progress toward a regulatory submission to initiate our Phase 2 trial of Rabeximod, it has been of essence to secure an experienced & trustworthy CRO with a proven global track record in planning, running, and compiling the results from clinical trials. We are happy to be able to initiate these early operational acitivites with the CRO who will support us in optimizing and running all aspects of the upcoming trial. We aim to develop a highly differentiated, safe, and effective treatment to patients suffering from rheumatoid arthritis and for patients underserved by available therapies," comments Tara Heitner, CEO, Cyxone.

Contact

Tara Heitner, CEO
Tel: +46 70 781 88 08
Email: [email protected]
Adelgatan 21
211 22 Malmö, Sweden

About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB, +46(0)8-528 00 399, [email protected]. For more information, please visit www.cyxone.com 

Nerladdningsbara filer

First Berlin Equity Research publicerar oberoende analys av Cyxone

Cyxone (publ), ett bioteknikföretag inom autoimmuna sjukdomar, meddelar idag att det internationellt renommerade analyshuset First Berlin har publicerat en oberoende analysrapport av bolaget.


Kommuniké från årsstämma i Cyxone AB den 16 maj 2022

Idag, den 16 maj 2022, hölls årsstämma i Cyxone AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet.




Cyxone AB rapporterar lovande terapieffekt av T20K/KORa kombinationsbehandling i en terapeutisk preklinisk modell av MS

Cyxone AB (CYXO), ett företag i klinisk fas som utvecklar transformativa terapier inom det autoimmuna området för att förse patienter med förbättrade behandlingsalternativ, meddelade idag resultat från sitt pågående samarbete med Medical University of Vienna.



Cyxone offentliggör framåtblickande strategi för läkemedelsutveckling med fokus på Rabeximod i studie på patienter med reumatoid artrit

Cyxone AB (CYXO), ett företag i klinisk fas som utvecklar transformativa behandlingar inom det autoimmuna området för att förbättra behandlingsresultatet för patienter, publicerade idag en framåtblickande strategi.



Kallelse till årsstämma i Cyxone AB

Aktieägarna i Cyxone AB, org. nr 559020-5471 ("Cyxone"), kallas härmed till årsstämma i Quality Hotel Views lokaler på Hyllie Stationstorg 29 i Malmö, måndagen den 16 maj 2022 kl. 10.00.


Notice of annual general meeting in Cyxone AB

The English text is an unofficial translation. In case of any discrepancies between the Swedish language version of this document and the English translation, the Swedish language version shall prevail.

The shareholders in Cyxone AB, Reg. No. 559020-5471 ("Cyxone"), are hereby invited to the annual general meeting to be held at the premises of Quality Hotel View at Hyllie Stationstorg 29 in Malmö, Sweden on Monday 16 May 2022 at 10:00 CEST.




Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted